article Open AccessTop 1% cited
Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen
Radiotherapy and Oncology · 2017 · Vol. 126(3) · pp. 519–526
Lauren E. Henke(Washington University in St. Louis)Rojano Kashani(Washington University in St. Louis)Clifford G. Robinson(Washington University in St. Louis)Austen Curcuru(Washington University in St. Louis)T.A. DeWees(Washington University in St. Louis)Jeffrey D. Bradley(Washington University in St. Louis)Olga Green(Washington University in St. Louis)Jeff M. Michalski(Washington University in St. Louis)Sasa Mutic(Washington University in St. Louis)Parag J. Parikh✉(Washington University in St. Louis)Jeffrey R. Olsen(University of Colorado Denver)
Abstract
SMART is clinically deliverable and safe, allowing PTV dose escalation and/or simultaneous OAR sparing compared to non-adaptive abdominal SBRT.
Advanced Radiotherapy TechniquesRadiation Dose and ImagingRadiation Therapy and DosimetryMedicineRadiologyRadiation therapyMagnetic resonance imagingNuclear medicineRadiosurgeryRadiation treatment planningMedical physics
MeSH terms
Abdominal NeoplasmsAgedFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedNeoplasm MetastasisProspective StudiesRadiotherapy DosageRadiotherapy Planning, Computer-AssistedRadiosurgeryImaging, Three-DimensionalOrgans at RiskRadiotherapy, Image-Guided
Funding
- Institute of Clinical and Translational Sciences
- ViewRay
- National Institutes of Health
- National Center for Advancing Translational Sciences
Citations
418
FWCI
39.06
field-weighted impact
References
37
Percentile
100%
vs. same field & year
Citations per year
References
Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma
Radiotherapy and Oncology · 2005 · 348 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.